Welcome to our dedicated page for Relay Therapeutics SEC filings (Ticker: RLAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Point72-related filers reported a 7.8% stake in Relay Therapeutics (RLAY). The Schedule 13G/A shows Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen collectively report shared voting and dispositive power over 13,445,704 shares of Relay common stock as of the close of business on June 30, 2025. The shares are held through Point72 Associates, an investment fund managed by Point72 Asset Management, and Cubist Systematic Strategies, LLC acted as a sub-advisor for a portion of the holdings. The filing includes a certification that the position was not acquired to influence control of the issuer.